NCT03699319 2025-01-23CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic CancerCase Comprehensive Cancer CenterPhase 1/2 Completed49 enrolled
NCT04593758 2023-05-24To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissueCornerstone PharmaceuticalsPhase 1/2 Completed16 enrolled